Siponimod - Isotope Labelled Standards
References
FAQ's
References
- Shifeng Pan, Wenqi Gao, Nathanael S Gray, Yuan Mi, Yi Fan, Immunosuppresant compounds and compositions, Novartis AG, US7939519B2, May 10, 2011
- Li, Wenkui; Luo, Suyi; Smith, Harold T.; Tse, Francis L. S., Quantitative determination of BAF312, a S1P-R modulator, in human urine by LC-MS/MS: Prevention and recovery of lost analyte due to container surface adsorption, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 878, Issue: 5-6, Pages: 583-589, 2010
Frequently Asked Questions
How is the purity of Siponimod assessed?
The purity of Siponimod is assessed using analytical methods such as HPLC or LC-MS to quantify the impurities present. The percentage of the active ingredient present in the drug substance helps calculate its purity.
What is forced degradation in the context of Siponimod?
Forced degradation is a stress testing process used to simulate the effect of different environmental factors on the stability of Siponimod. This process helps identify potential impurities that may form during storage or transportation.
How does Siponimod impurities profiling contribute to the development of Siponimod?
Impurity profiling helps identify and quantify impurities in Siponimod, which can help to optimize the manufacturing process and ensure the quality and safety of the drug.
What are the temperature conditions required to store Siponimod impurities?
Siponimod impurities are stored at a controlled room temperature between 2-8 ⁰C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.